Target intelligence / Profile preview

Glutamate ionotropic receptor kainate type subunit 3 (GluK3) (GluK3)

Target
GluK3
Molecular classification
Ion channel [1, 2], Receptor [1, 3], Glutamate receptor [2, 7], Kainate receptor [2, 12], Ligand-gated ion channel [1, 11]
01

Overview

Glutamate ionotropic receptor kainate type subunit 3 (GluK3) is a protein encoded by the GRIK3 gene that functions as a subunit of the ionotropic kainate-type glutamate receptor [1, 2]. It forms ligand-gated ion channels that are permeable to cations, primarily sodium and potassium, and sometimes calcium, mediating fast excitatory neurotransmission in the central nervous system [3, 11]. GluK3 is uniquely localized at both presynaptic and postsynaptic membranes, where it plays a critical role in modulating neurotransmitter release and regulating synaptic plasticity, particularly at hippocampal mossy fiber synapses [8, 13]. It is characterized by a relatively low affinity for glutamate and rapid desensitization compared to other kainate receptor subunits [12, 16]. Dysregulation or genetic variations in GluK3 have been linked to several neuropsychiatric and neurodevelopmental conditions, including schizophrenia, epilepsy, and developmental delay [2, 4, 5]. Additionally, aberrant expression of GluK3 has been observed in certain cancers, such as breast and colorectal cancer, where it may promote tumor progression [4, 6]. Pharmacological research has identified several agonists and antagonists, including selective compounds like Compound 28, which are being explored for their therapeutic potential in treating CNS disorders [8, 10].

Other names
GRIK3GLUR7GLR7EAA5Glutamate receptor ionotropic kainate 3GluR7aGluR7b
02

Mechanism of action

Agonism, competitive antagonism, and allosteric modulation of the ionotropic kainate receptor channel, which regulates cation influx and membrane depolarization [3, 8, 11, 17].

03

Biological functions

Signal transduction [1, 11]Synaptic transmission [2, 6]Excitatory neurotransmission [6, 11]Synaptic plasticity [3, 8, 13]Presynaptic modulation [8, 13, 16]Neurodevelopment [4, 5]
04

Disease associations

Schizophrenia [2, 4, 11]Epilepsy [3, 11]Neurodegenerative disease [11, 18]Developmental delay [2, 4, 5]Cancer [4, 6]Alcohol withdrawal [4]
05

Safety considerations

Excitotoxicity [11]Seizure risk [3, 18]Cognitive impairment [5, 11]Neurotoxicity [11]
06

Interacting drugs

Kainic acid [1, 6, 10]

8 more in the full profile.

07

Biomarkers

GRIK3 Ser310Ala polymorphism [4]1p34.3 microdeletion [5]GRIK3 mRNA expression levels in breast and colorectal cancer [4, 6]

Beyond the preview

Go deeper on Glutamate ionotropic receptor kainate type subunit 3 (GluK3) (GluK3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate ionotropic receptor kainate type subunit 3 (GluK3) (GluK3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call